Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals (Nasdaq: PCSA) will attend the 44th Annual J.P.

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA) will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12-15, 2026. CEO George Ng and Chief Business & Strategy Officer Patrick Lin will be available for one-on-one investor and partner meetings to discuss the company’s clinical pipeline, including the ongoing Phase 2 study of NGC-Cap in advanced or metastatic breast cancer.

Preliminary Phase 2 data reportedly show increased exposure to capecitabine metabolites with a safety profile comparable to capecitabine monotherapy. A formal interim analysis of the first 20 patients is expected in early 2026. Meeting requests can be directed to Wendy Guy at wguy@processapharmaceuticals.com.

Argus Jan 12 session

-6.55% close to close Open Argus

Details

News Market Reaction – PCSA

In the Jan 12 session, PCSA declined 6.55%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.5% in the session following this news. A negative reaction despite constructive c...

Analysis

The stock moved -6.5% in the session following this news. A negative reaction despite constructive clinical context could echo past divergence, such as the modest -1.73% move on a positive PCS499 poster update. Given operating losses of $3.44M in Q3 2025 and limited cash of $6.31M, investors may focus on funding and dilution risk. History shows sentiment has swung sharply around NGC-Cap data, so news flow and balance-sheet steps remain critical.

Key Figures

Interim analysis cohort: 20 patients Preliminary analyzed patients: 16 of 19 patients FBAL exposure change: Up to 10-fold reduction +5 more

Interim analysis cohort

20 patients

First 20 patients in NGC-Cap Phase 2 breast cancer trial interim analysis

Preliminary analyzed patients

16 of 19 patients

Initial NGC-Cap Phase 2 analysis as of Dec 17, 2025

FBAL exposure change

Up to 10-fold reduction

Reduction in FBAL catabolite exposure with NGC-Cap vs monotherapy

NGC-Cap dose

150 mg BID

Phase 2 NGC-Cap dosing schedule in breast cancer study

Mono-Cap dose

1,000 mg/m² BID

Standard capecitabine monotherapy arm dosing

Q3 2025 net loss

$3,436,573

Net loss for Q3 2025 per 10-Q

Cash balance

$6,308,420

Cash and cash equivalents as of Sept 30, 2025

Shares outstanding

56,644,223 shares

Common shares outstanding as of Nov 3, 2025

Historical Context

4 past events · Latest: Jan 05

4 events

1. Jan 05

   Clinical trial update

   24h Move

   +10.2%

   Completion of 20-patient enrollment for formal Phase 2 interim analysis.

2. Dec 17

   Clinical trial update

   24h Move

   +122.3%

   Preliminary Phase 2 NGC-Cap data showing increased active metabolite exposure.

3. Nov 05

   Conference presentation

   24h Move

   -1.7%

   Acceptance of PCS499 Phase 2/3 FSGS poster at ASN Kidney Week 2025.

4. Aug 07

   Strategic financing

   24h Move

   +1.6%

   Strategic investment and exploration of cryptocurrency treasury strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2, metastatic, capecitabine, monotherapy

4 terms

phase 2 medical

"including the ongoing Phase 2 study evaluating NGC-Cap in patients"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

metastatic medical

"NGC-Cap in patients with advanced or metastatic breast cancer."

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

capecitabine medical

"increases exposure to capecitabine’s cancer-killing metabolites while maintaining"

An oral chemotherapy prodrug that converts in the body into an active cancer-fighting agent similar to 5-fluorouracil; think of it as a timed-release package that becomes active after swallowing. It matters to investors because its use, safety profile, patent status and competition from generics or alternative treatments directly affect sales, clinical-program value and regulatory risk for companies involved in oncology medicines.

monotherapy medical

"comparable to standard capecitabine monotherapy."

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44^th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.

During the conference, Mr. Ng and Mr. Lin will be available for one-on-one meetings with investors and potential partners to discuss Processa’s clinical pipeline, including the ongoing Phase 2 study evaluating NGC-Cap in patients with advanced or metastatic breast cancer.

Preliminary Phase 2 data have demonstrated that NGC-Cap increases exposure to capecitabine’s cancer-killing metabolites while maintaining a safety profile comparable to standard capecitabine monotherapy. The Company expects to complete a formal interim analysis from the first 20 patients enrolled in early 2026.

Investors and interested parties who wish to schedule a meeting with Processa management during the conference are encouraged to contact Wendy Guy, Founder & Chief Administrative Officer (email: wguy@processapharmaceuticals.com).

About NGC-Cap (PCS6422+Capecitabine)

NGC-Cap is Processa’s lead oncology asset and a key component of its Next Generation Cancer (NGC) platform. When administered, NGC-Cap is designed to increase systemic exposure to active cancer-killing anabolite metabolites while reducing formation of toxic catabolite metabolites, potentially improving the therapeutic index of Capecitabine-based therapy.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value.

For more information, visit our website at www.processapharma.com.

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.

Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com

Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
PCSA@redchip.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Processa Pharmaceuticals (PCSA) attend the J.P. Morgan Healthcare Conference in 2026?

Processa will attend the conference in San Francisco on January 12-15, 2026.

Who from Processa Pharmaceuticals (PCSA) will be available for investor meetings at J.P. Morgan 2026?

CEO George Ng and Chief Business & Strategy Officer Patrick Lin will be available for one-on-one meetings.

What clinical program will Processa (PCSA) discuss at J.P. Morgan 2026?

Management will discuss the Phase 2 study of NGC-Cap in patients with advanced or metastatic breast cancer.

What do the preliminary Phase 2 data for NGC-Cap show according to Processa (PCSA)?

Preliminary data indicate NGC-Cap increases exposure to capecitabine metabolites while maintaining a safety profile comparable to capecitabine monotherapy.

When does Processa (PCSA) expect the interim analysis from the first 20 Phase 2 patients?

The company expects to complete a formal interim analysis from the first 20 patients in early 2026.

How can investors schedule a meeting with Processa (PCSA) at the J.P. Morgan conference?

Investors can request meetings by contacting Wendy Guy at wguy@processapharmaceuticals.com.